Anti-FHIT (pY114) Antibody
Rabbit polyclonal antibody to FHIT (pY114)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC |
---|---|
Primary Accession | P49789 |
Other Accession | O89106 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 16858 Da |
Gene ID | 2272 |
---|---|
Other Names | Bis(5'-adenosyl)-triphosphatase; AP3A hydrolase; AP3Aase; Diadenosine 5'5'''-P1P3-triphosphate hydrolase; Dinucleosidetriphosphatase; Fragile histidine triad protein |
Target/Specificity | Recognizes endogenous levels of FHIT (pY114) protein. |
Dilution | WB~~WB (1/500 - 1/1000), IH (1/50 - 1/200) |
Format | Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.09% (W/V) sodium azide. |
Storage | Store at -20 °C.Stable for 12 months from date of receipt |
Name | FHIT |
---|---|
Function | Possesses dinucleoside triphosphate hydrolase activity (PubMed:12574506, PubMed:15182206, PubMed:8794732, PubMed:9323207, PubMed:9543008, PubMed:9576908). Cleaves P(1)-P(3)-bis(5'-adenosyl) triphosphate (Ap3A) to yield AMP and ADP (PubMed:12574506, PubMed:15182206, PubMed:8794732, PubMed:9323207, PubMed:9543008, PubMed:9576908). Can also hydrolyze P(1)-P(4)-bis(5'-adenosyl) tetraphosphate (Ap4A), but has extremely low activity with ATP (PubMed:8794732). Exhibits adenylylsulfatase activity, hydrolyzing adenosine 5'-phosphosulfate to yield AMP and sulfate (PubMed:18694747). Exhibits adenosine 5'-monophosphoramidase activity, hydrolyzing purine nucleotide phosphoramidates with a single phosphate group such as adenosine 5'monophosphoramidate (AMP-NH2) to yield AMP and NH2 (PubMed:18694747). Exhibits adenylylsulfate-ammonia adenylyltransferase, catalyzing the ammonolysis of adenosine 5'- phosphosulfate resulting in the formation of adenosine 5'- phosphoramidate (PubMed:26181368). Also catalyzes the ammonolysis of adenosine 5-phosphorofluoridate and diadenosine triphosphate (PubMed:26181368). Modulates transcriptional activation by CTNNB1 and thereby contributes to regulate the expression of genes essential for cell proliferation and survival, such as CCND1 and BIRC5 (PubMed:18077326). Plays a role in the induction of apoptosis via SRC and AKT1 signaling pathways (PubMed:16407838). Inhibits MDM2-mediated proteasomal degradation of p53/TP53 and thereby plays a role in p53/TP53-mediated apoptosis (PubMed:15313915). Induction of apoptosis depends on the ability of FHIT to bind P(1)-P(3)-bis(5'-adenosyl) triphosphate or related compounds, but does not require its catalytic activity, it may in part come from the mitochondrial form, which sensitizes the low-affinity Ca(2+) transporters, enhancing mitochondrial calcium uptake (PubMed:12574506, PubMed:19622739). Functions as a tumor suppressor (By similarity). |
Cellular Location | Cytoplasm. Mitochondrion. Nucleus |
Tissue Location | Low levels expressed in all tissues tested. Phospho-FHIT observed in liver and kidney, but not in brain and lung Phospho-FHIT undetected in all tested human tumor cell lines |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
KLH-conjugated synthetic peptide encompassing a sequence within the center region of human FHIT (pY114). The exact sequence is proprietary.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.